IGM Biosciences (IGMS) Revenue & Revenue Breakdown
IGM Biosciences Revenue Highlights
Latest Revenue (Y)
$2.13M
Latest Revenue (Q)
$497.00K
IGM Biosciences Revenue by Period
IGM Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $2.13M | 99.25% |
| 2022-12-31 | $1.07M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | - |
IGM Biosciences generated $2.13M in revenue during NA 2023, up 99.25% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
IGM Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $497.00K | -23.66% |
| 2023-12-31 | $651.00K | 27.90% |
| 2023-09-30 | $509.00K | 13.62% |
| 2023-06-30 | $448.00K | -14.18% |
| 2023-03-31 | $522.00K | 40.32% |
| 2022-12-31 | $372.00K | 12.39% |
| 2022-09-30 | $331.00K | -9.56% |
| 2022-06-30 | $366.00K | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | - |
IGM Biosciences generated $497.00K in revenue during Q1 2024, up -23.66% compared to the previous quarter, and up 133.60% compared to the same period a year ago.
IGM Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HOWL | Werewolf Therapeutics | $19.94M | $742.00K |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| RNA | Avidity Biosciences | $9.56M | $2.04M |
| IKNA | Ikena Oncology | $9.16M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| IGMS | IGM Biosciences | $2.13M | $497.00K |
| BCEL | Atreca | $770.00K | $80.00K |
| DSGN | Design Therapeutics | - | - |
| CGEM | Cullinan Oncology | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| GRCL | Gracell Bio | - | - |
| CERE | Cerevel Therapeutics | - | - |
| ERAS | Erasca | - | - |
| PASG | Passage Bio | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
IGMS Revenue FAQ
What is IGM Biosciences’s yearly revenue?
IGM Biosciences's yearly revenue for 2023 was $2.13M, representing an increase of 99.25% compared to 2022. The company's yearly revenue for 2022 was $1.07M, representing an increase of 100.00% compared to 2021. IGMS's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is IGM Biosciences’s quarterly revenue?
IGM Biosciences's quarterly revenue for Q1 2024 was $497K, a -23.66% decrease from the previous quarter (Q4 2023), and a -4.79% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $651K, a 27.90% increase from the previous quarter (Q3 2023), and a 75.00% increase year-over-year (Q4 2022). IGMS's quarterly revenue for Q3 2023 was $509K, a 13.62% increase from the previous quarter (Q2 2023), and a 53.78% increase year-over-year (Q3 2022).
What is IGM Biosciences’s revenue growth rate?
IGM Biosciences's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.